Schizophrenia
Conditions
Keywords
Genetic polymorphism, Metabolic side effects of drugs, schizophrenia, Second-Generation Antipsychotic, Cannabinoid Receptor Type 1
Brief summary
The purpose of the study is to investigate these effects of Second-Generation Antipsychotic (SGAs) on glucose and lipid metabolic parameters in patients with schizophrenia, and explore the relationship between genes polymorphisms (such as drug metabolic enzyme, Endogenous Cannabinoid Receptor Type 1(CB1) and so on) and the SGAs-induced glucose and lipid metabolic disorder in Chinese Han persons with schizophrenia who are taking one of the SGAs(olanzapine, risperidone or ziprasidone).
Detailed description
SGAs now is used as the main tool to treat schizophrenia, however，the mechanism of glucose and lipid metabolism disorder it brings is still unclear. Based on the previous studies, the investigators found that the CB1 gene has a close connection with the metabolism disorder.The investigators suppose that the CB1 also has a significant role in regulation of energy and metabolism in hypothalamus. In this study ,the investigators will recruit 300 Patients with schizophrenia who defined by Diagnostic and Statistical Manual-5 (DSM-5), aged 18 to 60,and all the participants will receive a 6-week systematic treatment by one of the SGAs(including olanzapine, risperidone oral solution, ziprasidone capsules), and a battery of assessments of treatment effect and safety. Plasma concentration will be tested regularly, and these genes polymorphisms of CB1 and other associated with energy metabolism will be conducted by the second generation of gene detection techniques.This study could provide evidence and data to achieve the aim of individualized medication, reduce the drugs' side effect, also throw light on the production of medication for correct the metabolism disorder.
Interventions
None listed
Sponsors
Xijing Hospital
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* All cases must be in accordance with the DSM-5 schizophrenia or schizophreniform disorder diagnosis standards * Negative and positive symptom scale(PANSS)score ≥ 60 points;Aged 18 to 60 * Did not participate diet or other body mass reduction projects * Did not have physical illness which affects diet or activities * Did not use any antipsychotic drug within 2 weeks * Subject to consent by the Ethics Committee on clinical trials of drugs,Xijing hospital of The Fourth Military Medical University , all the participants signed a written informed consent
Exclusion criteria
* Pregnant or lactating women * Patients with serious body disease, such as epilepsy, liver and kidney impairment, digestive system diseases, etc * Obvious abnormalities on physical and laboratory examination * Body mass index(BMI)≥25.0;Fasting plasma glucose(FPG)≥6.1mmol/L or/and 2-hour postprandial blood glucose(2hPG)≥7.8mmol/L or/and somebody has been diagnosed with diabetes and treatment;Fasting triglycerides≥2.2mmol/L * Suffering from other mental disorders in line with DSM-5 diagnostic criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| identification of the effect of some genes polymorphism on the development of glucose and lipid metabolism disorder in patients with schizophrenia who are treated with the SGAs | measured at week 2 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| identification of the change of the body mass index in patients with schizophrenia who are treated with the SGAs | measured at baseline、week 2 and 6 | the ration of participants who are total remission after treatment |
| identification of the change of the level of Fasting Blood Sugar (FBS), 2 hours post prandial (2HPP) in patients with schizophrenia who are treated with the SGAs | measured at baseline、week 2 and 6 | — |
| identification of the change of the level of lipid profile in patients with schizophrenia who are treated with the SGAs | measured at baseline、week 2 and 6 | — |
| identification of the change of the level of fasting insulin in patients with schizophrenia who are treated with the SGAs | measured at baseline、week 2 and 6 | — |
Countries
China
Outcome results
None listed